Leerink Partnrs Has Bearish Estimate for Biogen Q2 Earnings

Biogen Inc. (NASDAQ:BIIB - Free Report) - Stock analysts at Leerink Partnrs lowered their Q2 2025 earnings per share estimates for shares of Biogen in a report issued on Sunday, April 13th. Leerink Partnrs analyst M. Goodman now expects that the biotechnology company will earn $4.05 per share for the quarter, down from their previous forecast of $4.10. The consensus estimate for Biogen's current full-year earnings is $15.83 per share. Leerink Partnrs also issued estimates for Biogen's Q3 2025 earnings at $3.96 EPS, Q4 2025 earnings at $4.19 EPS, FY2025 earnings at $14.90 EPS and FY2026 earnings at $16.30 EPS.

Biogen (NASDAQ:BIIB - Get Free Report) last posted its earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.43 by $0.01. Biogen had a net margin of 16.87% and a return on equity of 14.98%.

BIIB has been the topic of a number of other reports. Truist Financial lowered their price target on shares of Biogen from $220.00 to $210.00 and set a "buy" rating on the stock in a report on Thursday, February 13th. William Blair reaffirmed an "outperform" rating on shares of Biogen in a report on Monday, January 13th. Wells Fargo & Company cut their price objective on Biogen from $165.00 to $140.00 and set an "equal weight" rating for the company in a research note on Thursday, February 13th. Morgan Stanley decreased their target price on Biogen from $157.00 to $152.00 and set an "equal weight" rating on the stock in a research report on Wednesday, April 9th. Finally, Sanford C. Bernstein started coverage on Biogen in a research report on Tuesday, February 11th. They set a "market perform" rating and a $160.00 price target for the company. Eighteen investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $213.15.

Biogen Stock Performance

BIIB stock traded up $3.32 during trading on Tuesday, hitting $118.61. 1,206,280 shares of the company traded hands, compared to its average volume of 1,354,030. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.35 and a quick ratio of 0.90. The company has a market cap of $17.36 billion, a PE ratio of 10.60, a P/E/G ratio of 1.51 and a beta of 0.06. The stock's 50-day simple moving average is $134.29 and its 200 day simple moving average is $151.43. Biogen has a 1 year low of $110.04 and a 1 year high of $238.00.

Insider Transactions at Biogen

In other news, Director Stephen A. Sherwin sold 8,760 shares of the firm's stock in a transaction on Friday, March 7th. The stock was sold at an average price of $150.02, for a total value of $1,314,175.20. Following the transaction, the director now directly owns 11,318 shares in the company, valued at $1,697,926.36. This trade represents a 43.63 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.16% of the stock is currently owned by corporate insiders.

Institutional Trading of Biogen

A number of large investors have recently made changes to their positions in BIIB. Larson Financial Group LLC lifted its holdings in shares of Biogen by 640.9% in the fourth quarter. Larson Financial Group LLC now owns 163 shares of the biotechnology company's stock valued at $25,000 after purchasing an additional 141 shares in the last quarter. Lee Danner & Bass Inc. bought a new position in shares of Biogen during the 4th quarter worth approximately $25,000. Opal Wealth Advisors LLC acquired a new stake in Biogen during the 1st quarter valued at $26,000. Colonial Trust Co SC increased its holdings in shares of Biogen by 9,300.0% in the fourth quarter. Colonial Trust Co SC now owns 188 shares of the biotechnology company's stock valued at $29,000 after purchasing an additional 186 shares during the last quarter. Finally, OFI Invest Asset Management bought a new position in shares of Biogen in the fourth quarter valued at about $32,000. Institutional investors own 87.93% of the company's stock.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.